STAT1 Gain-of-Function (GOF) care technology platforms are the digital infrastructure underpinning modern management of STAT1 GOF disease — a rare autosomal dominant disorder caused by heterozygous gain-of-function mutations in the STAT1 gene encoding Signal Transducer and Activator of Transcription 1, the transcription factor that mediates type I interferon (IFN-α/β), type II interferon (IFN-γ), and type III interferon (IFN-λ) signaling through STAT1 homodimerization (gamma-activated factor, GAF) and ISGF3 complex formation, producing the clinical syndrome of Chronic Mucocutaneous Candidiasis (CMC) combined with susceptibility to invasive fungal infections, intracellular bacterial infections including mycobacteria and Salmonella, viral infections, and a spectrum of autoimmune complications — including thyroid autoimmunity, diabetes mellitus type 1, inflammatory bowel disease, hemolytic anemia, thrombocytopenia, systemic lupus-like disease, and aneurysm formation — driven by elevated and dysregulated STAT1 signaling that impairs Th17-cell differentiation, suppresses fungal immunity, and promotes autoreactive immune responses — integrating CMC surveillance dashboards, invasive fungal infection monitoring platforms, Th17-cell function tracking systems, autoimmune complication surveillance tools, aneurysm screening monitoring platforms, JAK inhibitor (ruxolitinib) therapy response systems, antifungal prophylaxis adherence tracking, and hematopoietic stem cell transplantation coordination dashboards that enable immunologists, infectious disease specialists, rheumatologists, and endocrinologists to detect Candida dissemination, aneurysm expansion, autoimmune flares, JAK inhibitor treatment failures, and therapeutic complications before they produce irreversible harm. When a STAT1 GOF care platform is unavailable or degraded, clinicians cannot access the Candida surveillance data, Th17-cell function results, autoimmune complication trends, aneurysm imaging results, and JAK inhibitor response data that guide treatment decisions across the overlapping chronic mucocutaneous candidiasis, invasive fungal susceptibility, autoimmune dysregulation, and vascular complication complexity of STAT1 GOF management, treatment coordination fails, and the longitudinal clinical monitoring that distinguishes stable STAT1 GOF from Candida dissemination, aneurysm rupture risk, autoimmune organ damage escalation, or JAK inhibitor toxicity collapses. STAT1 GOF — caused by heterozygous mutations in STAT1 that cluster in the coiled-coil domain and DNA-binding domain, impairing dephosphorylation of phospho-STAT1 through mutations that reduce the ability of nuclear STAT1 to be dephosphorylated by nuclear phosphatases, resulting in prolonged nuclear phospho-STAT1 occupancy, enhanced IFN-γ and IFN-α/β signaling, elevated expression of IFN-stimulated genes, and impaired signal termination — produces CMC through the paradoxical effect of excess IFN-γ signaling on Th17-cell differentiation: elevated STAT1 signaling promotes STAT1-mediated suppression of RORγt and IL-17 gene expression, impairing Th17-cell generation and IL-17 production that is essential for mucosal and cutaneous antifungal immunity, resulting in recurrent and chronic Candida infections of the oropharynx, esophagus, vagina, and skin despite intact adaptive immunity and normal or elevated T-cell counts; STAT1 GOF additionally produces susceptibility to invasive fungal infections (Aspergillus, Cryptococcus, Histoplasma), intracellular bacterial infections (mycobacteria, Salmonella, Brucella), and CMV disease through the combined effects of elevated IFN signaling on innate immune activation and impaired Th17-cell and Th1-cell polarization; STAT1 GOF causes autoimmune complications through elevated IFN-α/β-driven autoreactive immune activation, including thyroid autoimmunity (Hashimoto's thyroiditis, Graves' disease), type 1 diabetes mellitus, lupus-like disease, inflammatory bowel disease, autoimmune hepatitis, and autoimmune cytopenias; STAT1 GOF additionally causes cerebrovascular and large-vessel aneurysms through mechanisms involving elevated IFN-γ signaling in vascular endothelium and smooth muscle cells; treatment includes antifungal prophylaxis (fluconazole), JAK inhibitor therapy (ruxolitinib) to reduce STAT1 phosphorylation and restore Th17-cell function, aneurysm surveillance and prophylactic intervention, autoimmune disease management, and HSCT for severe refractory disease; monitoring platforms track Candida infection activity, Th17-cell function, autoimmune complication severity, aneurysm imaging results, JAK inhibitor response and toxicity, antifungal prophylaxis adherence, and vascular monitoring data critical to detecting treatment failures before they result in fungal dissemination, aneurysm rupture, or progressive autoimmune organ damage. The platforms that track Candida disease activity, Th17-cell function, autoimmune complication progression, aneurysm size and morphology, and JAK inhibitor response must remain continuously available — because missed Candida dissemination alerts, delayed aneurysm expansion detection, unmonitored autoimmune flares, and JAK inhibitor toxicity alerts lead to invasive candidiasis, aneurysm hemorrhage, irreversible autoimmune organ damage, and the treatment failures that define preventable morbidity and mortality in inadequately monitored STAT1 GOF patients.
This guide covers what STAT1 GOF care technology platforms need to monitor, why continuous availability matters across the spectrum of STAT1 gain-of-function chronic mucocutaneous candidiasis, autoimmune dysregulation, and vascular complication management, and how to build a monitoring strategy that protects Candida surveillance, Th17-cell monitoring, autoimmune complication tracking, aneurysm surveillance, JAK inhibitor management, and the CMC and immune dysregulation workflows that STAT1 GOF care requires.
Why STAT1 GOF Care Tech Platforms Cannot Afford Downtime
STAT1 GOF management is built on five pillars: monitoring chronic mucocutaneous candidiasis activity, esophageal Candida disease severity, and invasive fungal infection risk to detect Candida dissemination, esophageal stricture formation, and invasive Aspergillus or Cryptococcus disease requiring antifungal escalation; monitoring Th17-cell function and STAT1 phosphorylation status to assess the degree of immune dysregulation and guide JAK inhibitor therapy titration; tracking autoimmune complications across the thyroid, pancreas, gastrointestinal tract, liver, blood cells, and joints to detect organ damage that requires targeted immunosuppression while minimizing infection risk; coordinating aneurysm surveillance with serial vascular imaging to detect cerebrovascular and large-vessel aneurysm formation and expansion that requires prophylactic intervention before rupture; and managing JAK inhibitor therapy — ruxolitinib and other JAK1/2 inhibitors that reduce prolonged STAT1 phosphorylation and restore Th17-cell differentiation — with continuous therapy response monitoring and toxicity surveillance. The platforms that support STAT1 GOF programs must remain continuously available — because an unmonitored patient whose aneurysm surveillance imaging is missed due to a platform outage, or whose Candida esophagitis progresses to stricture during an antifungal adherence monitoring failure, represents a preventable catastrophe that timely digital monitoring could have averted through imaging escalation or antifungal intensification.
Chronic mucocutaneous candidiasis and invasive fungal surveillance defines the primary infection management challenge. STAT1 GOF causes CMC through Th17-cell deficiency from elevated STAT1-mediated IFN-γ signaling that suppresses IL-17 production and mucosal antifungal immunity; CMC manifestations include recurrent oropharyngeal candidiasis, Candida esophagitis with esophageal stricture risk, vulvovaginal candidiasis, Candida onychomycosis, and cutaneous candidal infections; invasive candidiasis and other invasive fungal infections (Aspergillus, Cryptococcus, dimorphic fungi) occur in STAT1 GOF patients with severe Th17-cell deficiency; antifungal prophylaxis adherence, fungal culture and PCR surveillance, esophageal disease monitoring, and invasive fungal infection threshold alert generation must be continuously integrated to detect CMC escalation and invasive fungal disease before dissemination occurs. Digital platforms that integrate fungal surveillance results, antifungal prophylaxis adherence monitoring, esophageal disease severity scoring, azole resistance testing result feeds, and Candida dissemination threshold alerts provide the fungal infection surveillance infrastructure that infection prevention requires.
Th17-cell function monitoring guides JAK inhibitor therapy and CMC risk stratification. The pathophysiological basis of CMC in STAT1 GOF is Th17-cell deficiency from elevated STAT1-mediated suppression of Th17 polarization; serial Th17-cell frequency measurement by flow cytometry, IL-17 production assay results, and STAT1 phosphorylation status quantification by intracellular phospho-STAT1 staining assess the degree of Th17-cell impairment and STAT1 hyperactivation that determines CMC severity and invasive fungal risk; JAK inhibitor therapy response is monitored through restoration of Th17-cell frequencies and IL-17 production alongside CMC clinical improvement. Digital platforms that track Th17-cell frequency, IL-17 production results, phospho-STAT1 levels, and JAK inhibitor response integration provide the immunological monitoring infrastructure that JAK inhibitor titration and therapy adequacy assessment require.
Aneurysm surveillance requires continuous vascular imaging coordination and expansion monitoring. STAT1 GOF causes cerebrovascular aneurysms — affecting intracranial arteries at the circle of Willis and brainstem feeding vessels — and large-vessel aneurysms affecting the aorta, renal arteries, and mesenteric vasculature, through mechanisms involving elevated IFN-γ signaling in vascular endothelium and smooth muscle that impairs vessel wall integrity; cerebral aneurysm rupture producing subarachnoid hemorrhage and large-vessel aneurysm rupture represent life-threatening vascular emergencies; serial MRI/MRA and CT angiography surveillance must be coordinated with size threshold escalation to neurosurgery or interventional radiology for prophylactic aneurysm treatment before rupture risk exceeds intervention risk. Digital platforms that track aneurysm size measurements, vascular imaging scheduling coordination, size threshold alert generation, neurosurgical consultation coordination, and post-intervention aneurysm surveillance provide the vascular monitoring infrastructure that prevents catastrophic aneurysm hemorrhage.
Autoimmune complication surveillance requires multi-organ monitoring across endocrine, gastrointestinal, hematological, and rheumatological domains. STAT1 GOF causes autoimmune complications driven by elevated IFN-α/β signaling — including Hashimoto's thyroiditis and Graves' disease, type 1 diabetes mellitus, IBD-like enteropathy, autoimmune hepatitis, autoimmune hemolytic anemia, immune thrombocytopenic purpura, systemic lupus erythematosus-like disease with anti-dsDNA and anti-Smith antibodies, and inflammatory arthritis — that require separate organ-specific monitoring streams coordinated through the STAT1 GOF care platform; autoimmune complications can emerge at any age in STAT1 GOF patients and can be the presenting manifestation before or independent of CMC; each autoimmune complication domain requires targeted immunosuppression that must be balanced against the ongoing infection risk from STAT1 GOF immunodeficiency and Th17-cell deficiency. Digital platforms that integrate thyroid function results, glucose monitoring, liver function tests, CBC with hemolysis markers, autoantibody panel results, IBD endoscopy data, and organ-specific autoimmune complication severity scores provide the multi-organ autoimmune surveillance infrastructure that STAT1 GOF management requires.
What to Monitor on a STAT1 GOF Care Tech Platform
Chronic Mucocutaneous Candidiasis Surveillance and Antifungal Management
The fungal infection surveillance service — integrating oropharyngeal and esophageal Candida culture result feeds, Candida species identification and azole resistance testing result tracking, esophageal disease severity score monitoring, antifungal prophylaxis adherence tracking (fluconazole, posaconazole, voriconazole), invasive candidiasis threshold alert generation, aspergillosis and cryptococcosis surveillance result integration, dimorphic fungal infection screening for endemic exposure, azole drug level monitoring, treatment-emergent azole resistance detection alerts, and CMC activity severity scoring — is the highest-priority infection monitoring target. Check at a 1-minute interval with immediate escalation. Candida surveillance defines the primary infection morbidity driver in STAT1 GOF; esophageal Candida disease can produce progressive stricture requiring dilation, and invasive candidiasis or aspergillosis can be life-threatening; platform failures that prevent antifungal adherence monitoring or fungal culture result access create infection management blind spots that allow CMC escalation and invasive fungal dissemination.
Th17-Cell Function and STAT1 Phosphorylation Monitoring
Monitor the Th17-cell immunological monitoring service — including Th17-cell frequency quantification by flow cytometry result feeds, intracellular IL-17A and IL-17F production assay result integration, phospho-STAT1 intracellular staining level result tracking, IFN-γ stimulation assay STAT1 phosphorylation kinetics results, JAK inhibitor therapy functional response monitoring (Th17-cell restoration evidence), IL-17 signaling pathway competence assessment, and immunological remission threshold alert generation — at a 1-minute interval. Th17-cell function monitoring quantifies the IL-17 immune deficiency that drives CMC severity and invasive fungal risk in STAT1 GOF; phospho-STAT1 level monitoring assesses the degree of STAT1 hyperactivation that determines treatment targets for JAK inhibitor therapy; platform failures that prevent Th17-cell assay access create risk stratification blind spots and prevent JAK inhibitor dose titration decisions.
Aneurysm Surveillance and Vascular Monitoring Platform
Monitor the vascular surveillance service — including cerebrovascular MRI/MRA result feeds and aneurysm size measurement tracking, intracranial aneurysm size threshold alert generation, CT angiography scheduling coordination for aortic and large-vessel surveillance, aortic diameter measurement trend monitoring, renal and mesenteric artery aneurysm surveillance result integration, size progression rate calculation with escalation thresholds, neurosurgical consultation referral coordination, interventional radiology coiling and surgical clipping post-procedure surveillance, and vascular imaging scheduling compliance monitoring — at a 1-minute interval. Aneurysm surveillance addresses the defining vascular catastrophe risk in STAT1 GOF; cerebral aneurysm rupture producing subarachnoid hemorrhage is a life-threatening emergency; platform failures that prevent aneurysm size tracking or imaging scheduling coordination delay the neurosurgical and interventional consultations that prevent aneurysm rupture.
JAK Inhibitor Therapy Response and Toxicity Monitoring
Monitor the JAK inhibitor management service — including ruxolitinib dose and schedule adherence tracking, CBC result feeds for JAK inhibitor hematological toxicity monitoring (anemia, thrombocytopenia, neutropenia), liver function test trend monitoring with hepatotoxicity alert generation, lipid panel monitoring, infection risk escalation assessment during JAK inhibitor use, CMC clinical response scoring relative to JAK inhibitor initiation, Th17-cell restoration trend integration with JAK inhibitor dose, phospho-STAT1 normalization tracking, treatment interruption impact monitoring, and dose adjustment alert generation — at a 1-minute interval. JAK inhibitor therapy is the most important targeted treatment for STAT1 GOF; ruxolitinib reduces excessive STAT1 phosphorylation and restores Th17-cell differentiation, with clinical improvement in CMC severity; JAK inhibitor toxicity monitoring platform failures prevent detection of hematological toxicity, hepatotoxicity, and opportunistic infections that require dose reduction or treatment interruption.
Multi-Organ Autoimmune Complication Surveillance
Monitor the autoimmune complication surveillance service — including thyroid function test result feeds (TSH, free T4, TPO antibody, TSH receptor antibody) with thyroid autoimmune alert generation, fasting glucose and HbA1c result tracking for type 1 diabetes monitoring, liver function test trend monitoring with autoimmune hepatitis alert generation, CBC result feeds with hemolysis markers (LDH, haptoglobin, direct antiglobulin test) for AIHA detection, platelet count threshold monitoring for ITP alert generation, ANA and anti-dsDNA antibody result feeds for lupus surveillance, inflammatory bowel disease clinical score and endoscopy result integration, inflammatory arthritis assessment coordination, organ-specific immunosuppression treatment response tracking, and multi-organ autoimmune severity composite scoring — at a 1-minute interval. Multi-organ autoimmune surveillance tracks the elevated IFN-α/β-driven autoimmune dysregulation that can affect virtually any organ system in STAT1 GOF; autoimmune complications require organ-targeted immunosuppression that must be carefully balanced against the Th17 and antifungal immunity deficits that increase CMC and invasive fungal risk during immunosuppression; platform failures that prevent autoimmune complication detection delay organ-protective interventions.
Intracellular Infection Surveillance
Monitor the intracellular pathogen surveillance service — including mycobacterial culture and PCR result feeds, nontuberculous mycobacteria and Mycobacterium tuberculosis surveillance, Salmonella and Brucella infection surveillance, CMV viral load monitoring, EBV viral load tracking, HSV surveillance, antimycobacterial treatment adherence monitoring, antiviral prophylaxis adherence tracking, intracellular infection activity composite scoring, and prophylaxis escalation alert generation — at a 1-minute interval. STAT1 GOF causes susceptibility to intracellular infections through impaired Th1-cell-mediated macrophage activation and IFN-γ-dependent antimicrobial responses that are paradoxically dysregulated despite elevated IFN-γ signaling amplitude; platform failures that prevent intracellular infection surveillance access delay the antimicrobial intensification that prevents disseminated mycobacterial, Salmonella, or CMV disease.
Telemedicine and STAT1 GOF Coordinator Platform
Monitor the telemedicine session API, primary immunodeficiency program nurse coordinator messaging, infectious disease consultation scheduling for fungal and intracellular infection management, rheumatology and gastroenterology consultation for autoimmune complication management, endocrinology consultation for thyroid and diabetes management, neurosurgery and interventional radiology consultation for aneurysm management, transplant medicine coordination, and remote consultation infrastructure at a 2-minute interval. STAT1 GOF management requires continuous coordination across immunology, infectious disease, rheumatology, endocrinology, gastroenterology, hepatology, hematology, neurosurgery, and transplant medicine; platform failures interrupt the multidisciplinary consultation that manages the overlapping CMC, autoimmune dysregulation, aneurysm risk, JAK inhibitor therapy, and HSCT coordination domains.
EHR Integration Endpoint
Monitor the EHR synchronization service at a 5-minute interval. STAT1 GOF patients presenting with fever, neurological symptoms, autoimmune flare, or oral or esophageal Candida symptoms require rapid provider access to their current Th17-cell function results, phospho-STAT1 levels, fungal culture data, antifungal prophylaxis adherence records, aneurysm surveillance imaging results, autoimmune complication severity scores, JAK inhibitor dose and toxicity data, and intracellular infection surveillance results.
Authentication Service
Monitor authentication at a 1-minute interval. Auth failures lock immunologists, rheumatologists, and STAT1 GOF care coordinators out of CMC surveillance platforms, aneurysm monitoring dashboards, JAK inhibitor management systems, and multi-organ autoimmune surveillance platforms simultaneously — disabling the entire STAT1 GOF digital management infrastructure.
SSL Certificates Across All Platform Domains
Monitor certificate expiry 30 days in advance across all patient-facing, clinician-facing, and integration domains.
Alerting Strategy for STAT1 GOF Care Tech Platforms
Immediate clinical escalation (24/7): Chronic mucocutaneous candidiasis surveillance and antifungal management, aneurysm surveillance and vascular monitoring, Th17-cell function and STAT1 phosphorylation monitoring, JAK inhibitor therapy response and toxicity monitoring, multi-organ autoimmune complication surveillance, authentication service. These affect real-time fungal infection detection, life-critical aneurysm monitoring, immunological function assessment, JAK inhibitor safety, and autoimmune organ damage detection that cannot tolerate delayed detection.
Immediate clinical operations escalation: Intracellular infection surveillance. Failures affect mycobacterial and viral surveillance that protect STAT1 GOF patients from disseminated intracellular infection.
High-priority immediate escalation: Telemedicine and STAT1 GOF coordinator platform. Access failures interrupt the multidisciplinary coordination that STAT1 GOF's overlapping CMC, aneurysm risk, autoimmune dysregulation, and JAK inhibitor management requires.
Business-hours engineering escalation: EHR synchronization. Investigate within one business hour.
Advance warning: SSL certificate expiry, 30 days in advance, across all patient-facing and integration domains.
Aneurysm surveillance and CMC monitoring require 24/7 alerting because STAT1 GOF creates vascular rupture risk and invasive fungal susceptibility that can escalate rapidly regardless of time of day — nighttime platform failures that prevent aneurysm size alert generation or block Candida dissemination surveillance create life-threatening monitoring gaps that cannot be recovered by daytime monitoring catch-up.
Status Page as a Clinical Safety Signal
Primary immunodeficiency program nurses and immunology coordinators managing after-hours contacts from STAT1 GOF families reporting severe headache, neurological symptoms, throat or esophageal symptoms, fever, or autoimmune flare need immediate platform status awareness before initiating escalation protocols. A published status page allows on-call coordinators to distinguish a platform incident from patient connectivity problems — and to initiate phone-based triage and emergency routing immediately when the digital platform is confirmed unavailable.
For STAT1 GOF programs coordinating CMC surveillance, aneurysm monitoring, Th17-cell function tracking, autoimmune complication surveillance, and JAK inhibitor management across geographically dispersed patients — many of whom receive care at specialized primary immunodeficiency centers managing the concurrent fungal infection, vascular, and autoimmune dysregulation domains simultaneously — a status page enables rapid identification of platform failures and activation of manual monitoring protocols. Publish the status page URL in care coordinator workstations, on-call immunology and infectious disease systems, neurosurgery program dashboards managing aneurysm surveillance, rheumatology and endocrinology coordinators managing autoimmune complications, and JAK inhibitor program pharmacists monitoring therapy response and toxicity.
The Business Case: CMC Control, Aneurysm Prevention, and STAT1 GOF Program Quality
STAT1 GOF specialty programs face significant cost exposure from invasive candidiasis in inadequately monitored patients whose antifungal adherence was not tracked, catastrophic aneurysm hemorrhages from missed aneurysm surveillance imaging, irreversible autoimmune organ damage from delayed complication detection and immunosuppression initiation, JAK inhibitor toxicity crises from inadequate hematological monitoring, and the catastrophic outcomes that occur when Candida dissemination, aneurysm expansion, multi-organ autoimmune damage, and Th17-cell deficiency accumulate without the continuous digital monitoring that enables antifungal intensification, neurosurgical intervention, organ-protective immunosuppression, and JAK inhibitor dose adjustment — with invasive candidiasis requiring ICU-level antifungal therapy, aneurysm subarachnoid hemorrhage requiring emergency neurosurgical intervention with high mortality, autoimmune organ damage requiring organ transplantation, and JAK inhibitor-associated cytopenias requiring treatment interruption and management of resulting infections. Successful CMC control, aneurysm surveillance, multi-organ autoimmune management, and JAK inhibitor optimization represent the highest-value interventions in STAT1 GOF management. Platform reliability that supports continuous Candida surveillance, vascular imaging coordination, Th17-cell monitoring, autoimmune complication tracking, and JAK inhibitor management is upstream of the most catastrophic outcomes in STAT1 gain-of-function chronic mucocutaneous candidiasis, immune dysregulation, and vascular complication care.
Missed aneurysm size threshold alerts that delay neurosurgical consultation and missed Candida dissemination alerts that allow invasive candidiasis to progress to sepsis represent preventable vascular and infection catastrophes that could have been detected by continuous digital monitoring and timely specialist coordination. Platforms that accurately capture Candida infection activity, Th17-cell function trends, phospho-STAT1 levels, aneurysm size measurements, autoimmune complication severity scores, JAK inhibitor response data, and intracellular infection surveillance results enable immunologists, rheumatologists, and neurosurgeons to distinguish expected STAT1 GOF variation from CMC dissemination, aneurysm rupture risk, autoimmune organ damage escalation, and JAK inhibitor toxicity before patients develop irreversible complications.
STAT1 GOF program quality metrics increasingly include invasive fungal infection incidence rates, aneurysm rupture rates, autoimmune complication organ damage severity scores, JAK inhibitor response rates, CMC activity scores, Th17-cell reconstitution rates with JAK inhibitor therapy, and time from aneurysm detection to intervention. Platform reliability is a direct input to outcome quality — programs whose monitoring platforms frequently fail will show higher invasive fungal infection rates from inadequate antifungal monitoring, more aneurysm hemorrhage events from missed imaging surveillance, worse autoimmune organ damage from delayed complication detection, and higher JAK inhibitor toxicity rates from inadequate hematological monitoring.
External monitoring from Vigilmon provides the documented, independent availability record that STAT1 GOF program directors can present to hospital administration and payer medical directors as evidence that the program's digital infrastructure supports the level of continuous CMC surveillance, aneurysm monitoring, Th17-cell tracking, and JAK inhibitor management that STAT1 gain-of-function disease care requires.
Vigilmon Setup for STAT1 GOF Care Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Chronic mucocutaneous candidiasis surveillance and antifungal management | 1 min | PagerDuty (immediate, 24/7) | | Aneurysm surveillance and vascular monitoring | 1 min | PagerDuty (immediate, 24/7) | | Th17-cell function and STAT1 phosphorylation monitoring | 1 min | PagerDuty (immediate, 24/7) | | JAK inhibitor therapy response and toxicity monitoring | 1 min | PagerDuty (immediate, 24/7) | | Multi-organ autoimmune complication surveillance | 1 min | PagerDuty (immediate, 24/7) | | Auth service | 1 min | PagerDuty (immediate) | | Intracellular infection surveillance | 1 min | PagerDuty (immediate) | | Telemedicine and STAT1 GOF coordinator platform | 2 min | PagerDuty + Slack (immediate) | | EHR synchronization endpoint | 5 min | Slack (business hours) | | SSL: all platform domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add the CMC surveillance and antifungal management platform at a 1-minute interval with 24/7 PagerDuty alerting
- Add aneurysm surveillance and vascular monitoring at a 1-minute interval with immediate 24/7 escalation — critical for life-threatening rupture prevention
- Add Th17-cell function monitoring and JAK inhibitor management at a 1-minute interval with immediate alerting
- Add multi-organ autoimmune complication surveillance at a 1-minute interval with immediate alerting
- Add intracellular infection surveillance at a 1-minute interval with immediate alerting
- Add authentication service and telemedicine coordinator platform monitoring
- Add EHR synchronization and SSL monitoring across all domains
- Configure neurosurgery team escalation channels for aneurysm size threshold alerts
- Publish the automatic status page URL in care coordinator workstations, on-call immunology and infectious disease systems, neurosurgery program dashboards, rheumatology and endocrinology coordinators, and JAK inhibitor pharmacists
Conclusion
STAT1 GOF care tech platforms hold the clinical surveillance infrastructure that makes STAT1 gain-of-function chronic mucocutaneous candidiasis, vascular complication, and multi-organ autoimmune dysregulation management survivable — CMC surveillance systems, aneurysm vascular imaging coordination platforms, Th17-cell function tracking dashboards, JAK inhibitor therapy management tools, multi-organ autoimmune complication monitoring systems, intracellular infection surveillance platforms, antifungal prophylaxis adherence monitoring tools, and phospho-STAT1 normalization tracking systems that cannot undo the invasive candidiasis fatalities, aneurysm subarachnoid hemorrhages, irreversible autoimmune organ damage, JAK inhibitor toxicity crises, and intracellular infection disseminations accumulated during periods of unmonitored Th17-cell deficiency, undetected aneurysm expansion, inadequately tracked antifungal prophylaxis adherence, and missed JAK inhibitor hematological toxicity. Their availability is a prerequisite for Candida infection detection, aneurysm expansion monitoring, Th17-cell function assessment, JAK inhibitor response tracking, autoimmune complication detection, intracellular infection surveillance, and the specialist access that patients with STAT1 GOF depend on throughout an illness that requires continuous fungal infection monitoring, vascular surveillance, Th17-cell tracking, JAK inhibitor management, multi-organ autoimmune monitoring, and intracellular infection prophylaxis management to maintain infection control, vascular safety, and autoimmune protection and detect the clinical signals — Candida dissemination, aneurysm size threshold crossing, Th17-cell frequency fall, phospho-STAT1 normalization failure, autoimmune organ damage escalation, thyroid autoimmunity emergence, platelet count fall, JAK inhibitor toxicity — that define STAT1 GOF deterioration before it progresses to invasive candidiasis, aneurysm rupture, irreversible autoimmune organ damage, and JAK inhibitor toxicity crises that define preventable morbidity and mortality in inadequately monitored STAT1 gain-of-function disease patients. When CMC surveillance platforms go offline, aneurysm monitoring fails, or JAK inhibitor management tracking systems are unavailable, the clinical consequences extend to a disease where the difference between adequate and inadequate monitoring is measured in the aneurysm subarachnoid hemorrhages that occur in patients whose imaging surveillance was missed, the invasive fungal disseminations that develop when antifungal prophylaxis adherence goes untracked, and the autoimmune organ damage that accumulates during the interval between autoimmune flare onset and the immunosuppression initiation that could have prevented irreversible thyroid destruction, hepatic fibrosis, and inflammatory bowel disease progression.
External monitoring from Vigilmon provides the independent, outside-in availability view that STAT1 GOF program directors and health system IT teams need to catch failures before they affect aneurysm surveillance or CMC monitoring — with the documented incident record that accreditation bodies and payer audit teams accept as evidence of operational maturity.
Start monitoring your STAT1 GOF care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and PagerDuty integration. No agent required. No credit card.
Tags: #monitoring #STAT1GOF #STAT1gainoffunction #chronicmucocutaneouscandidiasis #CMC #Th17deficiency #aneurysm #JAKinhibitor #ruxolitinib #autoimmunity #primaryimmunodeficiency #IFNsignaling #candidiasis #invasivefungalinfection #immunodeficiency #immunology #rheumatology #neurosurgery #healthtech #uptime #clinicaldocumentation #sre